Healio: PCSK9 inhibitors safe, effective in patients with heart transplants

October 12, 2020

In heart transplant recipients, PCSK9 inhibitors lowered LDL, stabilized coronary intimal hyperplasia and were associated with minimal adverse effects, according to data from the virtual Heart Failure Society of America Scientific Meeting.

Yasser Sammour, MD, internal medicine resident at Saint Luke’s Mid-America Heart Institute, and colleagues analyzed 68 patients from Saint Luke’s who received a heart transplant from 1999 to 2019 and were prescribed a PCSK9 inhibitor after the transplant.

Read the full article about the findings: Healio: PCSK9 inhibitors safe, effective in patients with heart transplants

Related Content

Healio: DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19
As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in
Healio: PET may be beneficial to guide revascularization strategy for CAD
PET perfusion and flow assessment may guide revascularization strategies for patients with carotid artery disease (CAD), according to a presentation at the Scientific Session and Exhibition of the American Society of Nuclear Cardiology.
Healio: Two studies provide further positive outcomes for empagliflozin in HF
Dr. Mikhail Kosiborod explains the results of the EMBRACE-HF study looking at the impact of empagliflozin in patients with HF and higher diastolic pulmonary artery pressure.